USPTO Examiner REYNOLDS FRED H - Art Unit 1658

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18749044EMBRYONIC ANGIOGENESIS MARKERS AND DIAGNOSTIC AND THERAPEUTIC STRATEGIES BASED THEREONJune 2024October 2025Allow1621NoNo
18648015PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAMEApril 2024March 2026Abandon2211NoNo
18636117ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICESApril 2024December 2025Allow2021NoNo
18616600METHODS FOR TREATING CANCERS USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONSMarch 2024January 2025Allow1000YesNo
18610009BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1)March 2024January 2026Abandon2201NoNo
18589590CYCLIC PEPTIDE ANTIVIRAL AGENTS AND METHODS USING SAMEFebruary 2024May 2025Allow1501YesNo
18590636STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTIONFebruary 2024April 2025Allow1310YesNo
18587927PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCEFebruary 2024October 2025Allow2011YesNo
18440920METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATEFebruary 2024August 2025Allow1820YesNo
18544721SEMAGLUTIDE DEPOT SYSTEMS AND USE THEREOFDecember 2023December 2025Abandon2331YesNo
18501864A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTSNovember 2023June 2025Abandon1901NoNo
18494535CLOTTING FACTOR PREPARATIONS FOR DELIVERY INTO TISSUE OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICEOctober 2023September 2024Allow1110YesNo
18483343METHOD FOR PROTEIN NANOWIRE SYNTHESIS AND TUNABLE CONTROL OF NANOWIRE LENGTHOctober 2023April 2025Allow1820YesNo
18374864MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOFSeptember 2023April 2025Abandon1811NoNo
18466548PEPTIDE COMPOUNDS AND METHODS OF USESeptember 2023April 2025Abandon1911NoNo
18231483CRYSTALLINE SALT FORMS OF BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2August 2023June 2024Allow1000YesNo
18272674Compositions And Methods of Synthesizing Shape Shifting Cyclic Peptides (Sscp) And Their Use in The Identification of Novel Therapeutic CompoundsJuly 2023November 2024Abandon1601YesNo
18352637UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAMEJuly 2023January 2025Abandon1810NoNo
18213575METHODS OF TREATING LIVER DISEASES COMPRISING AN IBAT INHIBITORJune 2023October 2025Abandon2730NoNo
18204576PROTEINOID COMPOUNDS, PROCESS OF PREPARING SAME AND USES THEREOFJune 2023February 2026Abandon3331YesNo
18322507BIOACTIVE PEPTIDES DERIVED FROM SNAKESMay 2023March 2024Allow1001YesNo
18143282PEPTIDOMIMETICS AND METHOD OF SYNTHESIS THEREOFMay 2023October 2024Abandon1811NoNo
18312100METHODS AND COMPOSITION INVOLVING THERMOPHILIC FIBRONECTIN TYPE III (FN3) MONOBODIESMay 2023January 2025Allow2111YesNo
18134277CYCLIC PROSAPOSIN PEPTIDES AND USES THEREOFApril 2023June 2025Abandon2620NoNo
18186724FUSION POLYPEPTIDE COMPRISING A FOREIGN ANTIGEN AND SELF ANTIGENMarch 2023March 2024Allow1210YesNo
18177651SYSTEMS AND METHODS FOR DELIVERY OF SPADIN FOR TREATMENT OF DEPRESSION OR OTHER INDICATIONSMarch 2023May 2025Abandon2630NoNo
18172062Compositions and Methods for Gene Therapy for Corneal Endothelium DisordersFebruary 2023October 2025Abandon3121NoYes
18170914SMALL MOLECULE DRUG CONJUGATESFebruary 2023October 2024Abandon2011NoNo
18018364PEPTIDE FOR TREATMENT OF CORONA VIRUS INFECTION DISEASE COVID-19 AND USE THEREOFJanuary 2023December 2025Allow3510YesNo
18158384ORTHOGONAL PROTEIN HETERODIMERSJanuary 2023July 2025Abandon3021NoNo
18016660Peptide, Peptide Salt, Pharmaceutical Composition and Biological Tissue Calcification InhibitorJanuary 2023October 2025Abandon3201NoNo
18155457METHOD FOR EXTRACTING KERATIN FROM WOOL/NATURAL FIBERS USING IONIC LIQUIDS REINFORCED WITH SONICATIONJanuary 2023September 2025Allow3251YesYes
18154745METHODS OF DIAGNOSING AND TREATING CD55 DEFICIENCY, HYPERACTIVATION OF COMPLEMENT, ANGIOPATHIC THROMBOSIS AND PROTEIN LOSING ENTEROPATHY (CHAPLE), A NEWLY IDENTIFIED ORPHAN DISEASEJanuary 2023August 2024Allow1911YesNo
18067760PEPTIDES FOR TREATMENT AND PREVENTION OF NONALCOHOLIC FATTY LIVER DISEASE AND FIBROSISDecember 2022July 2025Allow3031YesNo
18001913IL-10 MUTEINS AND FUSION PROTEINS THEREOFDecember 2022November 2025Allow3501YesNo
18078475PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERSDecember 2022March 2025Allow2721YesNo
18063494COMPOSITIONS FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASEDecember 2022April 2025Abandon2821NoNo
18057110Pharmaceutical composition including laminin fragments to treat or prevent the disease, disorder or symptom of tooth dentin and/or dental pulpNovember 2022April 2024Allow1710NoNo
18053981ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICESNovember 2022February 2024Allow1501YesNo
17977778TARGETED PHARMACOLOGICAL THERAPEUTICS IN UVEAL MELANOMAOctober 2022October 2024Abandon2421NoNo
18049917REVERSIBLE IMMOBILIZATION AND/OR CONTROLLED RELASE OF NUCLEIC ACID CONTAINING NANOPARTICLES BY (BIODEGRADABLE) POLYMER COATINGSOctober 2022July 2024Abandon2001NoNo
18047779METABOLICALLY STABLE PEPTIDE ANALOGSOctober 2022May 2024Abandon1911NoNo
17917420SOLUBLE ACE2 FOR TREATMENT OF COVID-19October 2022January 2026Abandon4001NoNo
17935177TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOFSeptember 2022November 2023Allow1411NoNo
17946380PEPTIDE LIGANDS FOR BINDING TO MT1-MMPSeptember 2022April 2025Abandon3021NoNo
17929980TOPICAL PHARMACEUTICAL FORMULATIONS OF A CYCLIC DEPSIPEPTIDESeptember 2022January 2026Abandon4001NoNo
17905747PHARMACEUTICAL FORMULATIONS POLYETHYLENE GLYCOL-BASED PRODRUGS OF ADRENOMEDULLIN AND USESeptember 2022March 2026Abandon4210NoNo
17901520CLOTTING FACTOR PREPARATIONS FOR DELIVERY INTO TISSUE OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICESeptember 2022July 2023Allow1100YesNo
17889754COLLAGEN HYDROLYSATE AS ACTIVE SUBSTANCE AGAINST PERIODONTITIS OR GINGIVITISAugust 2022October 2025Abandon3701NoNo
17885368SAFE DESMOPRESSIN ADMINISTRATIONAugust 2022May 2024Allow2110YesNo
17817252PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAMEAugust 2022June 2024Abandon2311NoNo
17812934ANTI-TUMOR POLYPEPTIDE Bax-BH3, FLUORESCENT POLYMERIC NANOMICELLE, PREPARATION METHOD AND USE THEREOFJuly 2022February 2024Allow1901YesNo
17859490METHODS FOR TREATING CANCERS USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONSJuly 2022January 2024Allow1811YesNo
17788264METHOD FOR PRODUCING PEPTIDEJune 2022January 2024Abandon1910NoNo
17807209MODIFIED ANTIMICROBIAL PEPTIDESJune 2022June 2025Allow3631YesNo
17837360COMPOUNDS AND METHODS FOR SELECTIVE C-TERMINAL LABELINGJune 2022June 2025Abandon3621YesYes
17782200Etelcalcetide intermediate and method for synthesizing etelcalcetideJune 2022December 2024Abandon3021NoNo
17826623METHODS AND COMPOSITIONS FOR MENISCAL REPAIR USING BIOADHESIVE PROTEINSMay 2022December 2024Abandon3011YesNo
17745104PROTEIN HYDROLYSATESMay 2022December 2024Abandon3141NoNo
17743835HEME SEQUESTING PEPTIDES AND USES THEREFORMay 2022August 2024Allow2721YesNo
17773734METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACIDMay 2022March 2025Allow3501YesNo
17712706METHODS AND COMPOSITIONS FOR VISUALIZING SUMOApril 2022January 2024Abandon2211NoNo
17766250COMPOSITIONS COMPRISING PEDF-DERIVED SHORT PEPTIDES (PDSP) AND USES THEREOFApril 2022December 2025Abandon4511NoNo
17765976ANTIMICROBIAL PEPTIDESApril 2022July 2025Abandon4010NoNo
17764184COMPOSITION AND APPLICATION THEREOF IN PREPARATION OF SKIN CARE PRODUCTS FOR REGULATING SKIN BIORHYTHMMarch 2022January 2026Abandon4621NoNo
17700120MODIFIED COLLAGENMarch 2022May 2025Abandon3721NoYes
17642936INHIBITING ZD17-JNK INTERACTION AS A THERAPY FOR ACUTE MYOCARDIAL INFARCTIONMarch 2022February 2026Abandon4721NoNo
17642082SKIN LIGHTENING COMPOSITIONMarch 2022March 2026Allow4821YesNo
17654060METHOD FOR PRODUCING PEPTIDE COMPOUND, REAGENT FOR FORMING PROTECTIVE GROUP, AND HYDRAZINE DERIVATIVEMarch 2022May 2025Abandon3841YesNo
17680778MITOCHONDRIAL-TARGETED ANTIOXIDANTS PROTECT AGAINST MECHANICAL VENTILATION-INDUCED DIAPHRAGM DYSFUNCTION AND SKELETAL MUSCLE ATROPHYFebruary 2022November 2023Abandon2010NoNo
17679925KV1.3 BLOCKERSFebruary 2022May 2023Allow1501YesNo
17650792NOVEL ANKYRIN REPEAT BINDING PROTEINS AND THEIR USESFebruary 2022May 2024Abandon2811YesNo
17634034Hydrophobic Peptide Salts for Extended Release CompositionsFebruary 2022November 2025Abandon4611NoNo
17588579Crystal Structures Comprising Elastin-Like PeptidesJanuary 2022February 2024Allow2511YesNo
17579408COMPOSITIONS, METHODS, KITS AND SYSTEMS FOR CANCER TREATMENT AND METABOLIC INTERVENTION THERAPY AND OTHER USESJanuary 2022May 2025Abandon3910NoNo
17573304PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USINGJanuary 2022February 2026Abandon4901NoNo
17572524CHIMERIC LYSM POYLPEPTIDESJanuary 2022October 2025Abandon4501NoNo
17571283PHARMACEUTICAL ASSOCIATION FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOFJanuary 2022October 2023Abandon2101NoNo
17625131Fusion Protein And Composition For Treating Animal TumorsJanuary 2022July 2025Allow4321YesNo
17569402UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAMEJanuary 2022October 2023Abandon2210NoNo
17567667COMPOSITIONS AND METHODS FOR DISASSEMBLING AMYLOID FIBRILSJanuary 2022June 2025Abandon4210NoNo
17624487Functionalized Nanoparticles and Their Use in Treating Bacterial InfectionsJanuary 2022May 2025Abandon4001NoNo
17561342MONOFUNCTIONAL BRANCHED POLYETHYLENE GLYCOL AND MODIFIED BIO-RELATED SUBSTANCE THEREOFDecember 2021November 2025Abandon4661YesNo
17621385THERAPEUTIC ANNEXIN-DRUG CONJUGATES AND METHODS OF USEDecember 2021November 2025Abandon4721NoNo
17620368PEPTIDE NUCLEIC ACID COMPOSITIONS WITH MODIFIED HOOGSTEEN BINDING SEGMENTS AND METHODS OF USE THEREOFDecember 2021October 2025Abandon4611NoNo
17553008DOSING REGIMENDecember 2021October 2023Abandon2201NoNo
17552087Cyclic Peptide Antiviral Agents and Methods Using SameDecember 2021May 2024Abandon2911NoNo
17617730SUPRAMOLECULAR STRUCTURESDecember 2021April 2025Abandon4001NoNo
17617675PHARMACEUTICAL PARENTERAL COMPOSITION OF DUAL GLP1/2 AGONISTDecember 2021October 2025Abandon4621YesNo
17542473Blood Coagulation-Promoting Silk Fibroin-Polypeptide Electrospun Membrane and Preparation Method ThereofDecember 2021August 2024Allow3201NoNo
17541636ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATIONDecember 2021March 2024Abandon2721NoNo
17535527ANTIBACTERIAL COMPOSITION EFFECTIVE IN TREATING GRAM NEGATIVE BACTERIAL INFECTIONS AND METHOD FOR PREPARING THE SAMENovember 2021November 2022Allow1201YesNo
17534427PH-Responsive Nanoparticles for Treating CancerNovember 2021September 2024Abandon3411NoNo
17613527PIC1 PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF HYPOXIC ISCHEMIC ENCEPHALOPATHYNovember 2021March 2025Abandon4001NoNo
17532307Peptide Compounds and Methods of Use in Wound HealingNovember 2021June 2023Allow1901YesNo
17529534Coversin Variants Lacking C5 BindingNovember 2021June 2024Allow3121YesNo
17528144Maytansinoid Derivatives, Conjugates Thereof, and Methods of UseNovember 2021January 2025Allow3841YesNo
17454665BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1)November 2021December 2023Allow2521YesNo
17595224NOVEL THERAPEUTIC AGENT FOR GASTROINTESTINAL CANCER AND METHOD FOR SCREENING FOR THE SAMENovember 2021March 2025Abandon4001NoNo
17518074CYCLIC PROSAPOSIN PEPTIDES AND USES THEREOFNovember 2021January 2023Allow1400YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner REYNOLDS, FRED H.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
19
Examiner Affirmed
11
(57.9%)
Examiner Reversed
8
(42.1%)
Reversal Percentile
64.7%
Higher than average

What This Means

With a 42.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
75
Allowed After Appeal Filing
11
(14.7%)
Not Allowed After Appeal Filing
64
(85.3%)
Filing Benefit Percentile
17.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 14.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner REYNOLDS, FRED H - Prosecution Strategy Guide

Executive Summary

Examiner REYNOLDS, FRED H works in Art Unit 1658 and has examined 359 patent applications in our dataset. With an allowance rate of 36.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner REYNOLDS, FRED H's allowance rate of 36.8% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by REYNOLDS, FRED H receive 2.50 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by REYNOLDS, FRED H is 36 months. This places the examiner in the 35% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +43.4% benefit to allowance rate for applications examined by REYNOLDS, FRED H. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 8.5% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 15.3% of cases where such amendments are filed. This entry rate is in the 16% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 76.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 61% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 56.8% of appeals filed. This is in the 29% percentile among all examiners. Of these withdrawals, 56.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 95.1% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.1% of allowed cases (in the 83% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.